Aminex Therapeutics

Aminex Therapeutics, Inc. is a privately held clinical-stage biotechnology company headquartered in Washington, Washington. With a small team of 5 to 9 employees, the company is dedicated to advancing innovative cancer treatments. Aminex Therapeutics generates an estimated $2.5 million in annual revenue. Aminex Therapeutics focuses on the development of a unique small molecule combination therapy, AMXT 1501 + DFMO, designed to treat a variety of cancer types. The company's research and development efforts have progressed from target discovery and patenting to pre-clinical research and now into clinical trials, offering hope for a significant advancement in cancer patient care. The company's commitment to innovation is evident in its proprietary small molecule combination therapy, which has shown promising results in pre-clinical studies. Aminex Therapeutics is dedicated to bringing its novel treatment to patients through rigorous clinical development and regulatory approval processes. For more information about Aminex Therapeutics and its groundbreaking research, please visit their website at aminextherapeutics.com.